Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Journal:

The New England Journal of Medicine

Published:

2025-11-09

DOI:

10.1056/nejmoa2512133

Affiliations:

25

Authors:

24

Go to article

Institutions	Authors	Share
Otsuka Pharmaceutical Co., Ltd., Japan	4.000000	0.17
University of Leicester, United Kingdom (UK)	2.000000	0.08
Peking University First Hospital, PKUHSC, China	1.000000	0.04
KJC Statistics Ltd, United Kingdom (UK)	1.000000	0.04
Juntendo University, Japan	1.000000	0.04
Mount Elizabeth Novena Hospital, Singapore	1.000000	0.04
British Hospital, Argentina	1.000000	0.04
Charles University (CU), Czech Republic	1.000000	0.04
Yonsei University, South Korea	1.000000	0.04
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.04
University of New South Wales (UNSW Sydney), Australia	1.000000	0.04
Maffei Centro Médico, Argentina	1.000000	0.04
Concord Repatriation General Hospital (CRG), USYD, Australia	1.000000	0.04
Complutense University of Madrid (UCM), Spain	1.000000	0.04
Stanford Medicine, United States of America (USA)	1.000000	0.04
Osmania General Hospital, India	1.000000	0.04
Colorado Kidney Care, United States of America (USA)	1.000000	0.04
Population Health Research Institute (PHRI), Canada	0.500000	0.02
John Hunter Hospital, Australia	0.500000	0.02
The University of Newcastle (UON), Australia	0.500000	0.02
McMaster University, Canada	0.500000	0.02
Manipal Academy of Higher Education (MAHE), India	0.250000	0.01
The George Institute - India (TGI India), India	0.250000	0.01
UNSW Bengaluru, India	0.250000	0.01
Imperial College London (ICL), United Kingdom (UK)	0.250000	0.01

Interested in Clinical Sciences?